XSHE
300637
Market cap355mUSD
Oct 09, Last price
10.10CNY
1D
-0.30%
1Q
14.51%
IPO
26.16%
Name
Zhejiang Yangfan New Materials Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yangfan New Materials (Zhejiang) Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ultraviolet (UV) curing products, sulfur-containing fine chemicals, and related new materials in China and internationally. The company offers 4-fluoro thiophenol, diphenyl sulfide, diphenyl disulfide, cyclopropanesulfonyl amide, and thioacetamide; and intermediates, including thiophenol, phenyl sulfide, thioanisole, thiofuran, pyridine and aniline, sulfone and sulfoxide, and other products. It also provides photoinitiators; and light-curable materials, such as HRI monomers and dispersions, high refractive index UV adhesives, optically bonding and electronic assembly UV adhesives, industrial bonding UV adhesives, and photosensitive resins for special applications. The company’s products are used in medicine, pesticides, dyes, and other fields. It also exports its products. In addition, the company provides technical services. The company was formerly known as Zhejiang Yangfan New Materials Co., Ltd. and changed its name to Yangfan New Materials (Zhejiang) Co., Ltd. in May 2025. Yangfan New Materials (Zhejiang) Co., Ltd. was founded in 2002 and is based in Hangzhou, China.
Key people
Yunming Shangguan
Chief Financial Officer
Xiangdong Fan
Vice President, Secretary of the Board · since 2025
Hui Liu
Vice President · since 2024
Junfei Zhu
Vice President · since 2024
Bin Fan
Executive Chairman of the Board · since 2025
Peiren Fan
Director · since 2020
Ming Tao
President, Director · since 2024
Jie Shen
Independent Director · since 2024
Weike Su
Independent Director · since 2021
Tangqing Yu
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||